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Determinants of enhanced thromboxane biosynthesis in renal Evidence supports the notion that the urinary excre-
transplantation. tion of unmetabolized thromboxane (TXB2) reflects intra-Background. Despite great improvement in patient and
renal production [2, 3], in contrast to the enzymatic me-graft survival, the long-term morbidity and mortality in renal
tabolites (11-dehydro-TXB2 and 2,3-dinor-TXB2), whichtransplant recipients (RTRs) are still significant, with a high
incidence of cardiovascular disease-related deaths. reflect mainly systemic extrarenal production [3, 4]. Stud-
Methods. We investigated thromboxane (TXA2) biosynthe- ies in patients with lupus nephritis, measuring the urinary
sis and endothelial and coagulative activation in 65 patients
excretion of TXB2 and 2,3-dinor-TXB2 have demon-who received a renal transplant.
strated a dissociation of their excretory pattern in theResults. The rate of TXA2 biosynthesis (urinary 11-dehydro-
TXB2 excretion largely reflects platelet TXA2 production in setting of renal disease [5]. Moreover, urinary excretion
vivo) was significantly (P , 0.0001) higher in RTRs than in of enzymatic thromboxane metabolites is increased in
healthy subjects. Plasma von Willebrand factor (vWF) and
patients with in vivo platelet activation [6–8].thrombin-antithrombin (TAT) complexes were significantly
Increased urinary excretion of 2,3-dinor-TXB2 hashigher (P , 0.001) in RTRs compared with controls. Urinary
11-dehydro-TXB2 directly correlated with plasma vWF and been reported in cyclosporine A nephrotoxicity (CsA)
cholesterol. We next examined the relative influence of in rats [9] and in humans [10]. Because in vitro CsA did
cyclosporine A (CsA) on TXA2 biosynthesis and endothelial not interfere with platelet arachidonic acid metabolismactivation, comparing a group of RTRs not receiving CsA with
in rats [9], it has been suggested that the cause of thean age- and sex-matched group of patients treated with CsA.
Urinary excretion of 11-dehydro-TXB2 and plasma levels of increased urinary excretion of 2,3-dinor-TXB2 is the con-
vWF were significantly increased in RTRs who received CsA sequence of intrarenal platelet activation, triggered bycompared with those who did not. After an overall follow-up
endothelial damage.of 120 months, RTRs who experienced cardiovascular events
had a higher frequency of abnormal plasma levels of vWF than Plasma measurements of von Willebrand factor (vWF)
patients who remained event free. may give a good indication of the degree of endothelial
Conclusion. Renal transplantation is associated with in vivo
perturbation [11]. It is synthesized by endothelial cellsplatelet activation highly related to endothelial activation. This
and secreted via constitutive and inducible pathways trig-is particularly evident in CsA-treated patients. Administration
of drugs that are able to reduce or eliminate thromboxane- gered by exposure to a wide array of inflammatory medi-
dependent platelet activation in vivo may be beneficial to re- ators [11]. In particular, vWF is an adhesive multimericduce the risk of cardiovascular events in RTRs.
glycoprotein, also contained in platelets and megakaryo-
cytes, that regulates platelet adhesion to the subendo-
thelium [11].Accelerated arterial disease is a leading cause of mor-
The aims of this study were as follows: (1) to evaluatetality in long-term survivors of renal transplantation [1].
the rate of thromboxane biosynthesis in a relatively large
group of renal transplant recipients (RTRs) and controlsKey words: von Willebrand factor, kidney transplantation, graft sur-
vival, cardiovascular disease, immunosuppression, nephrotoxicity. by measuring the urinary excretion of its major enzy-
matic metabolite 11-dehydro-TXB2; (2) to characterizeReceived for publication July 26, 2000
the determinants of altered thromboxane biosynthesisand in revised form November 3, 2000
Accepted for publication November 7, 2000 in this setting; (3) to explore the interplay between mark-
ers of endothelial damage, thrombin generation, andÓ 2001 by the International Society of Nephrology
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Table 2. Characteristics of the patients who never receivedTable 1. Characteristics of renal transplant recipients
cyclosporine compared with the patients who received cyclosporine
All Males Females
(N 5 65) (N 5 41) (N 5 24) Patients treated Patients who never
with cyclosporine received cyclosporine
Age years 40.5610.6 42.5610.9 37.269.4 (N 5 10) (N 5 10)
BMI 24.163.8 24.163.6 23.964.2
Dialysis time months 54.6636.3 55.6636.7 52.9636.3 Age years 42.3610.4 42.2610.3
BMI 24.866.5 24.463.1Post-transplantation
time months 56.9635.2 56.9637.7 57.0631.3 Dialysis time months 56.6642.9 64.9649.3
Post-transplantation timeFasting glucose levels
mg/dL 88.8612.7 91.1613.9 84.869.4 months 54.6630.6 79.9634.8
Fasting glucose levelsCreatinine levels
mg/dL 1.560.7 1.660.8 1.460.6 mg/dL 89.9613.0 86.9610.7
Creatinine levels mg/dL 1.460.2 1.560.6Prednisone dose
(N 5 64) mg/day 10.364.8 9.763.2 11.266.6 Prednisone dose mg/day 12.569.8 12.063.5
Cyclosporine doseCyclosporine dose
(N 5 55) mg/kg/day 3.661.2 3.561.2 3.661.2 mg/kg/day 3.161.2
Azathioprine dose mg/kg 62.3614.4 100.0623.6Azathioprine dose
(N 5 56) mg/kg 71.2625.3 69.2631.6 49.9633.9 Hypertension N (%) 7 (70) 5 (50)
b-blocker users N (%) 4 (40) 4 (40)Hypertension N (%) 44 (67.7) 29 (70.7) 15 (62.5)
b-blocker users Diuretic users N (%) 0 2 (20)
N (%) 30 (46.1) 22 (53.6) 8 (33.3)
Diuretic users N (%) 10 (15.4) 7 (17.1) 3 (12.5)
Cholesterol mg/dL 213.1642.1 205.3639.1 226.1644.7
Triglycerides mg/dL 149.4655.2 155.2659.7 139.4646.1
HDL-cholesterol All patients studied were on hemodialysis (54 6 37
mg/dL 52.5615.8 40.0614.9 60.1614.6
months; range 7 to 164) because of end-stage renal dis-LDL cholesterol
mg/dL 130.7635.2 126.2633.9 138.3639.3 ease prior to surgery.
Apolipoprotein A-I Patients were on an American Heart Association step
mg/dL 159.4633.9 149.5632.6 176.5629.4
I diet. They were not taking lipid-lowering drugs or anyApolipoprotein B
mg/dL 120.5626.2 120.6625.2 120.3628.3 drug known to interfere with the coagulation system or
platelet function during the previous month. Most ofAbbreviations are: BMI, body mass index; HDL, high-density lipoprotein;
LDL, low-density lipoprotein. them were hypertensive (N 5 44) and were treated with
b blockers or diuretics. All patients were taking predni-
sone (5 to 20 mg/day) or azathioprine (25 to 125 mg/day).
All but 10 were taking cyclosporine A (1.6 to 6.1 mg/kg/platelet activation; and (4) to examine the relative influ-
day). This group of 10 RTRs (Table 2) underwent renalence of cyclosporine treatment on these parameters.
transplantation before CsA was widely employed, and
they were available for study only 31 to 145 months after
surgery.METHODS
Subjects Follow-up
Sixty-five consecutive patients (24 women and 41 men, The vital status of the study patients was reviewed
aged 41 6 11 years, range 22 to 60 years) who had annually for 10 years to verify the occurrence of major
undergone cadaveric renal transplantation within the endpoints. For the survival analysis, myocardial in-
previous 57 6 35 months (range 2 to 145 months) and farction, cardiac death, and need of hemodialysis were
20 age-matched healthy subjects (7 women and 13 men, considered major end points. Nonfatal myocardial in-
aged 42.3 6 11.3 years, range 21 to 57 years) were asked farction (MI) was defined as rapid onset of typical symp-
to participate in the study (Table 1). Informed consent toms consistent with acute MI plus either typical electro-
was obtained from each participating subject. The inter- cardiographic changes (including new Q waves) or a
nal medicine review board of our institutions approved significant serum enzyme increase. Fatal MI was con-
the study protocol. firmed by a death certificate diagnosis plus preterminal
Specific exclusion criteria included the following: clini- hospitalization, with a definite or suspected diagnosis of
cal evidence of acute or ongoing allograft rejection, the MI within four weeks of death. Cardiac death was de-
presence of serious systemic disease unrelated to the fined as a death within 24 hours of the onset of severe
kidney, thrombocytopenia or a history of any disorder cardiac symptoms, unrelated to other known causes.
associated with bleeding, a history of coronary heart
Analysesdisease, diabetes mellitus, elevated serum liver enzymes,
and inability to refrain from the use of nonsteroidal anti- Urine was collected from each subject during the 12-
inflammatory agents (NSAIDs) for two weeks prior the hour period preceding blood sampling; the samples were
frozen immediately and kept at 2208C until extraction.study.
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Fig. 1. Urinary excretion rates of 11-dehydro-TXB2 in 65 renal trans-
plant recipients (RTRs) and 20 healthy subjects of equivalent age. The
dots represent individual measurements; horizontal bars represent mean Fig. 2. Correlation between plasma von Willebrand factor (vWF) and
value for each group (P , 0.0001). urinary excretion of 11-dehydro-TXB2 in 65 renal transplant recipients
(RTRs). Spearman’s rank correlation test yielded a statistically signifi-
cant coefficient of correlation (r 5 0.838, P 5 0.0001).
Immunoreactive 11-dehydro-TXB2 was extracted from
20 mL urine aliquots and measured by a previously vali-
by the Spearman rank correlation test. Prognostic valuesdated radioimmunoassay technique [7, 8].
of the variables under study were assessed by Kaplan–Blood samples were obtained by standard venopunc-
Meier method and were compared by long-rank test. Allture after a 12-hour fast. Whole blood was immediately
values are reported as means 6 1 SD. Statistical signifi-anticoagulated with ethylenediaminetetraacetic acid
cance was considered to be indicated by a value of P ,(EDTA; 1 mg/mL) and centrifuged at 3000 3 g at 48C
0.05. All calculations were made with the computer pro-for 10 minutes to obtain plasma. Samples were frozen at
gram Stat View (Abacus Concepts, Berkeley, CA, USA).2208C until assayed. Plasma concentrations of thrombin-
antithrombin complexes (TAT) were measured with an
enzyme immunoassay (Behringwerke AG, Marburg, RESULTS
Germany), as previously described [12]. Plasma vWF
Baseline characteristics of RTRs are shown in Table 1.antigen was determined with an enzyme immunoassay
The rate of TXA2 biosynthesis, as reflected by the(Asserachrom vWF-Ag; Boehringer Mannheim, Mann-
excretion of its major enzymatic metabolite, 11-dehydro-heim, Germany) as previously described [13]. For all
TXB2, was significantly (P , 0.0001) higher in RTRsassays, interassay and intra-assay coefficients of variation
(2055 6 1498 pg/mg creatinine; median, 1408; range,were ,8%.
161 to 7200) than in healthy subjects (329 6 132 pg/mgAll blood samples for the lipid studies were collected
creatinine; median, 284; range, 165 to 582). In 54 (83%)in tubes containing EDTA 1 mg/mL and separated
of the 65 patients, metabolite excretion was more thanwithin one hour after sampling. Total cholesterol (TC)
two standard deviations above the control mean (Fig. 1).and triglycerides were determined by an enzymatic
Plasma vWF was significantly (P , 0.001) increasedmethod. High-density lipoprotein-cholesterol (HDL-C)
in RTRs compared with those in healthy subjects (178 6was measured after phosphotungstic acid/MgCl2 precipi-
55 vs. 110 6 13%). In 45 (69%) of the 65 patients, plasmatation on fresh plasma. Low-density lipoprotein-choles-
vWF was more than two standard deviations above theterol (LDL-C) was calculated by the Friedewald’s for-
control mean. Plasma TAT complexes were significantlymula. Apolipoprotein (Apo) B and A1 were measured
higher in RTRs (4.6 mg/L; range, 1.7 to 28; P , 0.001)by nephelometric method. These procedures have been
compared with healthy individuals (2.4 mg/L; 1.7 to 4.12).described in detail elsewhere [7, 13].
Urinary 11-dehydro-TXB2 directly correlated with
Statistical analysis plasma vWF (r 5 0.84, P 5 0.0001; Fig. 2). No correlation
was found between thromboxane metabolite excretionThe data were analyzed by nonparametric methods to
and TAT levels. However, a weak direct correlation wasavoid assumptions about the distribution of the mea-
found between vWF and TAT levels (r 5 0.32, P 5 0.009).sured variables. An analysis of variance (ANOVA) was
Urinary 11-dehydro-TXB2 directly correlated withperformed with the Kruskal–Wallis method. Subsequent
plasma TC (r 5 0.39, P 5 0.001), LDL-C (r 5 0. 39, P 5pair-wise comparisons were made with the Mann–Whitney
0.001), and Apo B levels (r 5 0.32, P 5 0.0091).U test. Moreover, the association of eicosanoid measure-
ments with other biochemical parameters was assessed Because cyclosporine A has been associated with in-
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creased urinary excretion of TXB2 and 2,3-dinor-TXB2,
we next examined the relative influence of immunosup-
pressant therapy on TXA2 biosynthesis and endothelial
activation. Ten RTRs (3 women and 7 men, aged 42 6
10 years) who never received CsA were matched for
sex, age, and months after surgery with 10 RTRs who
received CsA (Table 2). The two groups of patients were
comparable for lipid parameters and dialysis time. The
RTRs who did not receive CsA (group I) were studied
80 6 35 months after surgery in comparison to 55 6 31
months of the group II that received CsA (P 5 0.0506).
Urinary excretion of 11-dehydro-TXB2 was signifi-
cantly increased in group II (3067 6 2003 pg/mg creati-
nine) compared with both controls (344 6 142, P 5
0.0004) and group I (979 6 477 pg/mg creatinine, P 5
0.0047). Patients who received CsA also had higher levels
of vWF compared with controls and those of patients
who did not receive CsA (213 6 51 vs. 107 6 10, P 5
0.0064, and vs. 151 6 36%, P 5 0.0011, respectively;
Fig. 3).
Plasma levels of TAT were not significantly increased
in group II (3.8 mg/L, range 2.3 to 15) compared with
those in group I (4.0 mg/L, 2 to 28); meanwhile, control
subjects had significantly lower plasma levels (2.3 mg/L,
1.7 to 4.1; P 5 0.013) than the CsA-treated group.
Follow-up
The overall duration of follow-up was of 120 (109 6
23; range 14 to 120) months. One patient died from lung
cancer, and three patients were lost to follow-up because
they refused to undergo the scheduled visits. These four
patients were excluded from the survival analysis.
During a median follow-up of 90 (86 6 29; range 14
to 120) months, 16 patients experienced major endpoints.
There were five cardiac deaths, six acute myocardial
infarctions (1 fatal and 5 nonfatal), and five patients
who needed hemodialysis. These patients had a similar
Fig. 3. Urinary excretion rates of 11-dehydro-TXB2 (A; P 5 0. 0069)pattern of all variables investigated in the study com-
and plasma vWF (B; P 5 0.0076) in 10 RTRs taking cyclosporinepared with patients who remained event free. Neverthe-
and in 10 RTRs who never received cyclosporine. The dots represent
less, patients who experienced major endpoints during individual measurements; horizontal bars represent mean value for each
group.follow-up had a higher frequency of abnormal vWF
plasma levels (94 vs. 67%, P 5 0.03) at the baseline
than patients who remained event free. In particular, all
patients who experienced acute myocardial infarction or
DISCUSSIONcardiac death during the follow-up had abnormal vWF
Cardiovascular disease is the major cause of mortalityplasma levels at the baseline. Among patients who
in RTRs [14–17]. The high rate of cardiovascular diseaseneeded hemodialysis, all but one showed baseline vWF
has been due to a cluster of risk factors, including dyslipi-values more than two standard deviations above the con-
demia and hypertension [18, 19].trol mean.
Because thromboxane-dependent platelet activationUnivariate analysis of survival showed that plasma
has been considered responsible for, or at least a contrib-values of vWF in excess of the mean 6 2 SD of control
utor of, acute thromboembolic complications such assubjects was significantly related to cumulative endpoints
myocardial infarction and ischemic stroke [17], we(log rank 5 3.8, P , 0.05) as well as to cardiovascular
events (log rank 5 4.2, P , 0.04). sought to determine whether the systemic formation of
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thromboxane A2 is altered in vivo through measurement mal levels of vWF and TAT, an index of thrombin gener-
of a major metabolite (11-dehydro-TXB2) in the urine ation, in RTRs with enhanced thromboxane biosynthesis
of RTRs. In fact, native unmetabolized TXB2 in urine provides in vivo evidence for the concomitant occurrence
reflects thromboxane production by the kidney, while 11- of these events, and suggests that platelet activation and
dehydro-TXB2 or 2,3-dinor-TXB2 primarily may reflect thrombin generation may be a consequence of endothe-
systemic thromboxane biosynthesis [2–8, 20, 21]. Endo- lial damage or dysfunction.
thelial cell activity was evaluated in vivo by determina- Based on current evidence, vascular complications
tion of circulating levels of vWF, synthesized and se- might be a consequence of long-standing endothelial in-
creted by the endothelial cells. vWF is an adhesive jury and the accompanying platelet activation and throm-
multimeric glycoprotein, also contained in platelets and bin generation.
megakaryocytes, that regulates platelet adhesion to the We also report the first evidence, to our knowledge,
subendothelium [11]. The circulating vWF pool is de- that RTRs who received cyclosporine had significantly
rived mainly from endothelial cells [11], and high plasma higher in vivo platelet and endothelial activation than
vWF levels have been proposed as a marker of endothe- RTRs who were not on CsA immunosuppression. In-
lial damage [11, 22]. creased urinary excretion of 2,3-dinor-TXB2 has been
Sixty-nine percent of our patients showed plasma lev- previously demonstrated in rat [9] and human [10] CsA
els of vWF more than two standard deviations above nephrotoxicity. In vitro CsA did not interfere with plate-
the control mean, strongly indicating that vascular endo- let thromboxane generation when rat platelet-rich plasma
thelium is altered in RTRs. Elevated levels of vWF have was exposed to CsA and then challenged with adenosine
been described earlier in CsA-treated RTRs [23]. In diphosphate (ADP) or arachidonate [9]. However, in
this report, we provide biochemical evidence for the humans, Jorkasky et al reported increased production
occurrence in RTRs of thromboxane-dependent platelet of thromboxane by platelets exposed to cyclosporine
activation in vivo, and demonstrate that this activation [28], and cyclosporine may activate platelet arachidonate
is highly related to peripheral signs of altered endothelial metabolism in the systemic circulation directly [29–31].
cell function. Moreover, the follow-up data suggest that Moreover, by increasing the production of reactive oxy-
endothelial perturbation may represent a link between gen species, CsA may induce endothelial damage
in vivo platelet activation and the occurrence of cardio- [32–34], at the renal circulation activating platelets and
vascular events. macrophages during their passage through the renal cir-
This process may be exacerbated by the frequent oc- culation. On the other hand, human platelets exposed
currence of hyperlipidemia after transplantation [24]. to cyclosporine have an impaired ability to mediate vaso-
Hyperlipidemia may be due to alterations in metabolism
dilation. This appears to be caused by a compound re-
and nutritional status that occur after successful trans-
leased by cyclosporine-exposed platelets that interferesplantation, with reversal of chronic renal failure. More-
with nitric oxide-dependent vasodilation [35].over, drugs used for immunosuppression and the frequent
In conclusion, we have characterized an exquisitelyuse of diuretics and b blockers to treat hypertension
sensitive marker of platelet activation, which is abnormalinduced by cyclosporine may also affect lipoprotein me-
in approximately 80% of RTRs even several monthstabolism [25]. Because abnormal cholesterol levels are
after surgery. Although the mechanisms responsible forrelated to persistent thromboxane-dependent platelet
platelet activation are likely to be multifactorial in thisactivation [26], we correlated urinary 11-dehydro-TXB2
disease (for example, endothelial injury, disease-or treat-levels to cholesterol or LDL-C levels in RTRs. The weak
ment-related metabolic disorders), we show that renalcorrelation between the two suggests that thromboxane-
transplantation is associated with in vivo platelet activa-dependent platelet activation is only partly a conse-
tion and highly related to endothelial activation. This isquence of abnormal cholesterol levels.
particularly evident in the CsA-treated patients. More-Renal transplant recipients show increased plasma
over, the follow-up study showed that plasma vWF levelsTAT complexes, consistent with coagulative activation
are significantly related to cardiovascular endpoints.in vivo. In fact, TAT complexes result from the neutral-
The analytical approach we have used may help iden-ization of thrombin by its principal naturally-occurring
tify those patients at increased thrombotic risk as poten-inhibitor [27]. However, the lack of correlation between
tial candidates for antiplatelet therapy [20]. Of course,urinary excretion of 11-dehydro-TXB2 and plasma TAT
long-term, prospective clinical studies are needed to verifycomplexes excludes that increased thrombin generation
the validity of the proposed sequence of events and toinduces platelet activation. Platelet and coagulative acti-
determine the prognostic value of abnormal thrombox-vation may be related to the presence of endothelial
ane biosynthesis vis-a`-vis other indexes of vascular in-activation, as demonstrated by the correlation between
jury, including vWF levels. Moreover, controlled clinicalplasma vWF levels and both urinary 11-dehydro-TXB2
and plasma TAT levels. Therefore, our finding of abnor- trials of low-dose aspirin may help define the pathophysio-
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